Indivior Pharmaceuticals, Inc.
INDVHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeIndivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and. Valued at $4.79B, INDV is a mid-cap name in its sector. It develops medicines to treat substance use disorders.
Market Cap
$4.79B
Beta
1.15
P/E (TTM)
20.79
P/E (Fwd)
9.79
EPS (TTM)
$1.95
EPS (Fwd)
$4.14
ROE
—
ROA
22.7%
Cash
$175.0M
Total Debt
$509.0M
Free CF
$44.3M
52W Change
153.2%
Annual Financials
Cash vs Debt
Indivior Pharmaceuticals, Inc. carries $509.0M in total debt against $175.0M in cash reserves — debt is roughly 2.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $44.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on assets of 22.7% further supports the picture of efficient asset utilization. Revenue has grown from $901.0M (2022) to $1.24B (2025), reflecting a 38% increase over the period.
As with any equity investment, INDV carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing INDV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.